We provided evidence that ACER3 upregulation mediates the pathogenesis of NASH by reducing the hepatic levels of C18:1-ceramide, which protects hepatocytes from oxidative stress in response to overload of palmitic acid. This evidence concerns the gene ACER3 and metabolic dysfunction-associated steatohepatitis.